Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.

Barchart

Handmaid’s Tale fans ‘cannot believe’ ending of first episode of season six: ‘It was worth the wait’

Hulu’s hit dystopian show is airing its final season in the U.S.

The Independent UK

10 top new movies and shows to stream this weekend on Netflix, Max and more (April 11-13)

'The White Lotus' finale, 'Dying for Sex' and 'Black Bag' lead my weekend watch list

Tom’s Guide

From analysis to the latest developments in health,
read the most diverse news in one place.

"The Handmaid's Tale": America's finale

We've watched June run in and out of Gilead and now we're running with her

Salon

The Handmaid’s Tale season 6: UK release date, cast, plot and how to watch

Fans can expect the final instalment to deliver the ultimate showdown between the rebels, led by Elizabeth Moss’s June, and Gilead

Evening Standard

Praise be, loyal ‘Handmaid’s Tale’ fans: Propulsive final season promises a satisfying catharsis

Praise be

The Independent UK

'The Handmaid's Tale' Season 6 Review: Hulu's Brutal Dystopian Show Finally Gets An Ending

After eight years of fascist dystopia, June Osborne finally gets to rest.

Inverse

Read news from The Economist, FT, and more,
with one subscription

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

Barchart

UNAIDS chief urges Donald Trump to make an 'amazing deal' to end HIV

The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV.

Euronews

AIDS pandemic risks 'resurging globally' amid US funding halt: UN

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, the UN's top AIDS official said Monday, warning millions would die.

Radio France Internationale

UNAIDS director proposes that President Trump make an 'amazing deal' to end HIV

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and will cost many lives of the world’s most vulnerable people

The Independent UK

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

Barchart

How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?

As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

TechRadar

The Handmaid's Tale season 6: everything we know so far about the hit Hulu show’s return

The Handmaid's Tale season 6 returns to Hulu on April 8 – here's everything we know about the dystopian drama's return.

Barchart

Stock Index Futures Slip on Trump Tariffs, Powell’s Testimony on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President Donald Trump and looked ahead to Federal Reserve Chair Jerome Powell’s congressional testimony as well as Wednesday’s release…

Barchart

Gilead Sciences Stock: Is Wall Street Bullish or Bearish?

Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences is likely to report its fiscal fourth-quarter earnings next month, and analysts are expecting a modest fall in its earnings.

StockNews.com

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

Barchart

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Benzinga

Looking At Gilead Sciences's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).

The Independent UK

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

International Business Times

Fewest New HIV Cases Since Late 1980s: UNAIDS Report

Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.